New potential instrument to fight hepatocellular cancer by restoring p53

Hepatitis Monthly

Volumn 11, Issue 5, 2011, Pages 331-332

  Vincent, Franklin C ^a   Los, Marek J ^b,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b BioApplications Enterprises Winnipeg   (Canada)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Acetogenins HBV X protein; Annonaceous; Hepatocellular carcinomas; Toll like receptors

Indexed keywords

ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; DEACETYLUVARICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER INVASION; CANCER SURVIVAL; CELL PROLIFERATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; EDITORIAL; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; HUMAN; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

EID: 79957638724     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Editorial

References (19)

1. Mackiewicz J, Mackiewicz A. Design of clinical trials for therapeutic cancer vaccines development. Eur J Pharmacol. 2009;625 (1-3):84-9.
2. Gokay O, Kuhner D, Los M, Gotz F, Bertsche U, Albert K. An ef-cient approach for the isolation, identifcation and evaluation of antimicrobial plant components on an analytical scale, demonstrated by the example of Radix imperatoriae. Anal Bioanal Chem. 2010;398(5):2039-47.
3. Los M. New, exciting developments in experimental therapies in the early 21st century. Eur J Pharmacol. 2009;625(1-3):1-5.
4. McFarlane A, Orriss GL, Stetefeld J. The use of coiled-coil proteins in drug delivery systems. Eur J Pharmacol. 2009;625(1-3):101-7.
5. McLaughlin JL. Paw paw and cancer: annonaceous aceto-genins from discovery to commercial products. J Nat Prod. 2008;71(7):1311-21.
6. Solomon RV, Lee H. Chloroquine and its analogs: a new promise of an old drug for efective and safe cancer therapies. Eur J Pharmacol. 2009;625(1-3):220-33.
7. Alali FQ, Liu XX, McLaughlin JL. Annonaceous acetogenins: recent progress. J Nat Prod. 1999;62(3):504-40.
8. Chavez D, Acevedo LA, Mata R. Tryptamine derived amides and acetogenins from the seeds of Rollinia mucosa. J Nat Prod. 1999;62(8):1119-22.
9. Cassady JM, Baird WM, Chang CJ. Natural products as a source of potential cancer chemotherapeutic and chemopreventive agents. J Nat Prod. 1990;53(1):23-41.
10. Koike K, Tsutsumi T, Fujie H, Shintani Y, Kyoji M. Molecular mechanism of viral hepatocarcinogenesis. Oncology. 2002;62(Suppl 1):29-37.
11. Kato N, Yoshida H, Ono-Nita SK, Kato J, Goto T, Otsuka M, et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology. 2000;32(2):405-12.
12. Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene. 1993;8(5):1109-17.
13. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specifc DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A. 1994;91(6):2230-4.
14. Lee H, Kim HT, Yun Y. Liver-specifc enhancer II is the target for the p53-mediated inhibition of hepatitis B viral gene expression. J Biol Chem. 1998;273(31):19786-91.
15. He HB, Wu XL, Yu B, Liu KL, Zhou GX, Qian GQ, et al. The efect of desacetyluvaricin on the expression of TLR4 and P53 protein in Hepg2.2.15. Hepat Mon. 2011;11(5):[Epub ahead of print].
16. French SW, Oliva J, French BA, Li J, Bardag-Gorce F. Alcohol, nutrition and liver cancer: role of Toll-like receptor signaling. World J Gastroenterol. 2010;16(11):1344-8.
17. Matijevic T, Pavelic J. Toll-like receptors: cost or beneft for cancer? Curr Pharm Des. 2010;16(9):1081-90.
18. Hombach-Klonisch S, Paranjothy T, Wiechec E, Pocar P, Mustafa T, Seifert A, et al. Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch Immunol Ther Exp. 2008;56(3):165-80.
19. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wes-selborg S, Schulze-Osthof K, et al. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med. 2008;14(10):450-60.